Investors/Media

RSS Content

Infinity to Present at the 2017 BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the 2017 BIO CEO & Investor Conference in New York City on Monday, February 13, 2017. During the conference, Joseph Pearlberg, M.D., Ph.D., vice president, clinical development at Infinity will participate in a panel at 11:00 a.m. ET entitled, "CAR-T, TILs, and Bispecifics: Immuno-Oncology Challenges and Opportunities."

Additionally, Adelene Perkins, Infinity's chair and chief executive officer will provide an overview of the company on Monday, February 13, at 3:00 p.m. ET. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com and will be available for 90 days following the event.

About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Contact:
Jaren Irene Madden, Senior Director,
Investor Relations and Corporate Communications
617-453-1336 or Jaren.Madden@infi.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-to-present-at-the-2017-bio-ceo--investor-conference-300402020.html

SOURCE Infinity Pharmaceuticals, Inc.